The Jumpstart Our Business Startups (JOBS) Act – which the president has indicated he will sign into law, now that it has passed both the House and Senate – will significantly impact small biotechs by providing new fundraising options and easing the burden of complying with securities laws.
MAP Pharmaceuticals Inc. confirmed late Monday what the rumor mills had already deduced: The company received a complete response letter from the FDA for Levadex, its orally inhaled formulation of intravenous migraine drug dihydroergotamine (DHE).
When the number crunchers released their 2011 venture analyses earlier this year, they sparked debate about just how bad – or perhaps good – the fundraising environment for start-up biotechs really was.
Decades of improvement in drug discovery technology have failed to improve productivity, and with the patent cliff now at hand, some pharma firms are adopting a back-to-basics approach. When it comes to getting back to basics, Traditional Chinese Medicine is "about as low-tech as it comes," said David Kolb, founder and CEO of Insero Health Inc.
PaxVax Corp. is gearing up for Phase III trials with PXVX-0200, a fast-acting cholera vaccine designed to target both developing countries and the more lucrative travelers' market – exemplifying PaxVax's "double bottom-line" mission, according to the firm's executive vice president and chief operating officer, Nima Farzan.
Shares of OncoGenex Pharmaceuticals Inc. fell 20.8 percent Friday after the Bothell, Wash.-based biotech priced its $50 million public offering at $12 per share.
Decades of improvement in drug discovery technology have failed to improve productivity, and with the patent cliff now at hand, some pharma firms are adopting a back-to-basics approach.
The article I wrote last week for FierceBiotech on the relationship between Series A funding and innovation led to an interesting discussion with Bruce Booth, partner at Atlas Venture and biotech blogger extraordinaire. The crux of my article was this: We (as an industry) obsess over funding for innovative start-ups because we worry that one day, big pharma will look around and realize they’ve run out of assets to in-license. So we need to look not only at the amount of Series A funding biotech raise, but at which biotechs are raising it, and whether they are really doing innovative...
Cancer vaccines, long the red-headed stepchildren of biotech, were briefly catapulted into the limelight by Dendreon Corp.'s 2010 approval of Provenge (sipuleucel-T) only to be dragged back down by that drug's disappointing sales.
What was always known to be a high-risk, high-reward proposition proved to be more the former than the latter as Anthera Pharmaceuticals Inc.'s Phase III trial of varespladib was halted for futility.
